Olema Pharmaceuticals Inc [OLMA] stock is trading at $5.52, up 7.39%. An important factor to consider is whether the stock is rising or falling in short-term value. The OLMA shares have gain 5.34% over the last week, with a monthly amount drifted -17.86%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Olema Pharmaceuticals Inc [NASDAQ: OLMA] stock has seen the most recent analyst activity on April 02, 2024, when Goldman initiated its Buy rating and assigned the stock a price target of $24. Previously, Citigroup started tracking the stock with Buy rating on January 30, 2024, and set its price target to $20. On July 21, 2023, Oppenheimer initiated with a Outperform rating and assigned a price target of $21 on the stock. CapitalOne started tracking the stock assigning a Overweight rating and suggested a price target of $16 on May 05, 2023. Credit Suisse initiated its recommendation with a Outperform and recommended $12 as its price target on February 22, 2023. In a note dated June 09, 2022, H.C. Wainwright upgraded an Buy rating on this stock but restated the target price of $12.
Olema Pharmaceuticals Inc [OLMA] stock has fluctuated between $4.60 and $16.77 over the past year. Currently, Wall Street analysts expect the stock to reach $27 within the next 12 months. Olema Pharmaceuticals Inc [NASDAQ: OLMA] shares were valued at $5.52 at the most recent close of the market. An investor can expect a potential return of 389.13% based on the average OLMA price forecast.
Analyzing the OLMA fundamentals
Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -72.14%, Pretax Profit Margin comes in at -65.12%, and Net Profit Margin reading is -65.12%. To continue investigating profitability, this company’s Return on Assets is posted at -0.53, Equity is -0.54 and Total Capital is -0.68. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.27 points at the first support level, and at 5.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.65, and for the 2nd resistance point, it is at 5.79.
Ratios To Look Out For
For context, Olema Pharmaceuticals Inc’s Current Ratio is 7.10. On the other hand, the Quick Ratio is 7.10, and the Cash Ratio is 1.17.
Transactions by insiders
Recent insider trading involved Bain Capital Life Sciences Inv, 10% Owner, that happened on Jan 08 ’25 when 0.3 million shares were purchased. Director, Graham G. Walmsley completed a deal on Dec 17 ’24 to sell 0.7 million shares. Meanwhile, Affiliate Logos Opportunities Fund I LP bought 0.7 million shares on Dec 13 ’24.
